[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356634-105":59,"doc-detail-356634-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","safety-of-68gaga-fapi-46-petct-hemodynamic-measurements-and-patient-reported-outcomes-in-cancer-patients","Safety of [68Ga]Ga-FAPI-46 PET/CT - hemodynamic measurements and patient-reported outcomes in cancer patients","","Fibroblast activation protein inhibitor (FAPI) shows promising oncologic diagnostic performance, yet formal safety evaluation of FAPI PET/CT remains limited. This study assessed safety and tolerability of [68Ga]Ga-FAPI-46 PET/CT, focusing on hemodynamic parameters, adverse events, and patient-reported discomfort. Participants received 150–250 MBq tracer and underwent serial blood pressure and heart-rate measurements plus AE/discomfort assessments at baseline, multiple post-injection timepoints, and 1 day. Thirty participants were included. No patient-reported discomfort or clinically relevant hemodynamic AEs were found; three systolic BP increases were classified as AEs. A statistically significant heart-rate decrease was observed and attributed to prescan anxiety. ",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/safety-of-68gaga-fapi-46-petct-hemodynamic-measurements-and-patient-reported-outcomes-in-cancer-patients/356634/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/safety-of-68gaga-fapi-46-petct-hemodynamic-measurements-and-patient-reported-outcomes-in-cancer-patients/356634.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What safety outcomes were evaluated for [68Ga]Ga-FAPI-46 PET/CT?","Question",{"text":113,"@type":114},"The study evaluated hemodynamic parameters (systolic/diastolic blood pressure and heart rate), adverse events, and patient-reported discomfort at predefined baseline and post-injection timepoints, plus 1 day after scanning.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was [68Ga]Ga-FAPI-46 administered and what imaging preparation was used?",{"text":118,"@type":114},"Participants received 150–250 MBq [68Ga]Ga-FAPI-46, followed by low-dose, non-contrast CT. Hemodynamic measurements and AE/discomfort assessments were performed at scheduled moments after injection.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings regarding adverse events and blood pressure changes?",{"text":122,"@type":114},"No patient-reported adverse events or discomfort attributable to [68Ga]Ga-FAPI-46 were reported, and no clinically relevant hemodynamic adverse events were observed. However, three participants had systolic blood-pressure increases classified as adverse events.",{"name":124,"@type":111,"acceptedAnswer":125},"How did heart rate change after the scan and what was the interpretation?",{"text":126,"@type":114},"Heart rate decreased statistically from baseline to post-scan (77 bpm to 73 bpm). The decrease was interpreted as likely reflecting prescan nervousness.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},356634,1790816239,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":46,"preview_page_count":19,"preview_urls":149},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","DOI: 10.1111/cpf.70064  \nORI G INA L ART I CLE  \nSafety of [68Ga]Ga‐FAPI‐46 PET/CT including hemodynamic measurements and patient‐reported outcomes in cancer patients  \nMorten Bentestuen1,2  | Camilla Sylvest3  | Svend B. Jensen1,4  | Lara R. Soro1 | Aage Knudsen3 | Morten Ladekarl2,5  | Ole Thorlacius‐Ussing2,6  | Wolfgang P. Fendler7  | Helle D. Zacho1,2   \n1Department of Nuclear Medicine and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark  \n2Department of Clinical Medicine, Aalborg University, Aalborg, Denmark  \n3Department of Gynaecology and Obstetrics, Aalborg University Hospital, Aalborg, Denmark  \n4Department of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark 5Department of Oncology and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark  \n6Department of Gastrointestinal Surgery and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark 7Department of Nuclear Medicine, West German Cancer Center, DKTK and NCT site, University Hospital Essen, Essen, Germany  \nCorrespondence  \nMorten Bentestuen, Department of Nuclear Medicine, Aalborg University Hospital, Hobrovej 18‐22, 9000 Aalborg, Denmark. [Email:](Email: m.bentestuen@rn.dk)[ m.bentestuen@rn.dk](Email: m.bentestuen@rn.dk)  \nFunding information  \nAlfred Benzon Foundation; Region of North Jutland Health Research Foundation  \nAbstract  \nIntroduction Aim: Fibroblast activation protein inhibitor (FAPI) has demonstrated promising oncological diagnostic performance. Although no adverse events (AEs) have been previously reported, a formal safety evaluation of FAPI PET/CT is lacking. This study aimed to assess the safety and tolerability of [⁶⁸Ga]Ga‐FAPI‐46 PET/CT, with a focus on hemodynamic parameters, AEs, and patient‐reported discomfort. Materials and Methods: Participants were included from two ongoing prospective diagnostic trials: (1) FAPI PET/CT in ovarian cancer (EU CTIS no. 2023‐505938‐ 98‐00) and (2) FAPI PET/CT in gastric and gastroesophageal junction cancer (EU CTIS no. 2023‐505916‐40‐01) . A dose of 150–250 MBq [⁶⁸Ga]Ga‐FAPI‐46 was administered, and low‐dose, non‐contrast CT was performed. Hemodynamic parameters, including systolic and diastolic blood pressure (BP) and heart rate (HR), were measured at baseline, 1‐min post‐injection (p. i.), 10 min p. i., and post‐scan. Additionally, potential AEs and discomfort were assessed at these timepoints and 1 day p. i., and participants were instructed to report events. AEs were graded according to the Common Terminology Criteria for Adverse Events version 5 .0. Results: Thirty participants were included. No patient reported AEs or discomfort attributable to [⁶⁸Ga]Ga‐FAPI‐46, and no significant changes in mean systolic or diastolic BP were observed; however, three patients experienced increases in systolic BP classified as AEs. A clinically non‐relevant but statistically significant (p \u003C0.01) decrease in HR (from 77 bpm at baseline to 73 bpm at post‐scan) was observed. Conclusion: [⁶⁸Ga]Ga‐FAPI‐46 PET/CT is well tolerated with no immediate patient‐ reported discomfort or clinically relevant hemodynamic AEs. The observed decrease in HR from baseline to post‐scan likely reflects prescan nervousness.  \nKEYWO R DS  \nadverse events, FAPI, fibroblast activation protein inhibitor, oncology, PET, safety  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s) . Clinical Physiology and Functional Imaging published by John Wiley & Sons Ltd on behalf of Scandinavian Society of Clinical Physiology and Nuclear Medicine.  \nClin Physiol Funct Imaging. 2026;46:e70064 . [https://doi.org/10.1111/cpf.70064](https://doi.org/10.1111/cpf.70064)  \n[wileyonlinelibrary.com/journal/cpf](wileyonlinelibrary.com/journal/cpf)  \n1 of 8  ","cbCaiceuAkQZi2AR","https://ap.wps.com/l/cbCaiceuAkQZi2AR","pdf",1124180,"English","# Introduction\n## Safety rationale and study gap\n## FAPI biology and cancer relevance\n## Prior therapeutic experience with FAP inhibition","[{\"question\":\"What safety outcomes were evaluated for [68Ga]Ga-FAPI-46 PET/CT?\",\"answer\":\"The study evaluated hemodynamic parameters (systolic/diastolic blood pressure and heart rate), adverse events, and patient-reported discomfort at predefined baseline and post-injection timepoints, plus 1 day after scanning.\"},{\"question\":\"How was [68Ga]Ga-FAPI-46 administered and what imaging preparation was used?\",\"answer\":\"Participants received 150–250 MBq [68Ga]Ga-FAPI-46, followed by low-dose, non-contrast CT. Hemodynamic measurements and AE/discomfort assessments were performed at scheduled moments after injection.\"},{\"question\":\"What were the main findings regarding adverse events and blood pressure changes?\",\"answer\":\"No patient-reported adverse events or discomfort attributable to [68Ga]Ga-FAPI-46 were reported, and no clinically relevant hemodynamic adverse events were observed. However, three participants had systolic blood-pressure increases classified as adverse events.\"},{\"question\":\"How did heart rate change after the scan and what was the interpretation?\",\"answer\":\"Heart rate decreased statistically from baseline to post-scan (77 bpm to 73 bpm). The decrease was interpreted as likely reflecting prescan nervousness.\"}]","Safety of [68Ga]Ga-FAPI-46 PET/CT - hemodynamic measurements and patient-reported outcomes in cancer patients | PDF",1790126497,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1aff556bb3b14522e96c4cbfd42c159f.webp",983,1291,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba364b7502c1d7350db9a42147ba72cb.webp",982,1290,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89fa1e3d93ad3421b5e29e4fd898ece4.webp",981,1289,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/248ff20e59dac2bfb0db4faff194be85.webp",980,1287]